Seven Eight Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Seven Eight Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-70,697	Closed	-$1.79M	–	783
2023 Q2	$1.79M	Buy	70,697 +61,788	+694%	+$1.92M	0.3%	107
2023 Q1	$287K	Buy	+8,909	New	+$278K	0.06%	341
2020 Q2	–	Sell	-11,289	Closed	-$167K	–	596
2020 Q1	$167K	Buy	+11,289	New	+$234K	0.04%	414

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Seven Eight Capital's RVNC Position: Q3 2023 in Review

Seven Eight Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 70,697 shares — an estimated $1.79M sold.

Seven Eight Capital first reported a position in RVNC in Q1 2020 and held it in 3 quarters. The position peaked at $1.79M in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Seven Eight Capital reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Seven Eight Capital sold 70,697 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $1.79M.
Seven Eight Capital first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 3 quarters.
Seven Eight Capital's Revance Therapeutics, Inc. position peaked at $1.79M in Q2 2023.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.